Weight loss for patients with NAFLD is the key to improvement of histopathologic features. Find out what else you know about treatment of NAFLD/NASH with 8 guidance-based questions.
The American Association for the Study of Liver Diseases (AASLD) outlines a data‐supported approach to the treatment nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in a guidance document published in Hepatology.
While disease-specific pharmacotherapy is still in clinical trials, there are a number of recommended approaches to management using existing medications and non-drug intervention. Find out what you know about these with the following 8 questions.